Center-Authored Papers

Filters: Author is Budde, Lihua E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE et al..  2013.  A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.. British journal of haematology. 161(2):183-91. Abstract
Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC et al..  2013.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.. PloS one. 8(12):e82742. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
J
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.  2010.  Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.. Journal of immunology (Baltimore, Md. : 1950). 184(8):4284-94. Abstract
R
Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ et al..  2016.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.. Cancer immunology research. Abstract
T
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE et al..  2012.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.. Blood. 119(17):3940-50. Abstract
W
Wang X, Wong CLW, Urak R, Mardiros A, Budde LE, Chang W-C, Thomas SH, Brown CE, Rosa CL, Diamond DJ et al..  2015.  CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Wang X, Wong CLW, Urak R, Taus E, Aguilar B, Chang W-C, Mardiros A, Budde LE, Brown CE, Berger C et al..  2016.  Comparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer.. Oncoimmunology. 5(1):e1072671. Abstract
Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard SM, Mott MR, Norris AP, Wong CLW, Urak RZ, Chang W-C et al..  2016.  Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL.. Blood. 127(24):2980-2990. Abstract